PF-08634404

Phase 3Biologic

Pfizer

PF-08634404 is one of 129 biologic programs targeting Carcinoma, Hepatocellular. It is currently in Phase 3.

Indications

Total Trials

Active Trials

128

Competitors

Pipeline

Status by Indication[3][1]

Indication

Carcinoma, HepatocellularRecruiting

Intestinal NeoplasmRecruiting

Carcinoma, Renal CellRecruiting

Non-Small Cell Lung CarcinomaRecruiting

Small Cell Lung Cancer ( SCLC )Recruiting

Urothelial CancerRecruiting

Advanced Non-Small Cell Lung CancerRecruiting

Endometrial NeoplasmsNot yet recruiting

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal AdenocarcinomaRecruiting

Small Cell Lung CancerRecruiting

Carcinoma, HepatocellularPreclinical

Recruiting

Intestinal NeoplasmPhase 3

Recruiting

Carcinoma, Renal CellPreclinical

Recruiting

Non-Small Cell Lung CarcinomaPreclinical

Recruiting

Small Cell Lung Cancer ( SCLC )Preclinical

Recruiting

Urothelial CancerPreclinical

Recruiting

Advanced Non-Small Cell Lung CancerPhase 3

Recruiting

Endometrial NeoplasmsPhase 3

Not yet recruiting

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal AdenocarcinomaPreclinical

Recruiting

Small Cell Lung CancerPhase 2

Recruiting

Competition

Competitive Landscape

154 competitors in Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

33 2

Imfinzi

AstraZeneca

Phase 3

30 3

Tecentriq

Roche

Phase 3

27 4

Camptosar

Pfizer

Phase 3

26 5

Keytruda

Merck & Co.

Phase 3

20 6

Avastin

Roche

Phase 3

16 7

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

96 8

Vepesid

Opdivo

Tarlatamab-Dznl

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Urothelial Cancer

NCT07421700

Q4 2028

PreclinicalRecruiting

Carcinoma, Hepatocellular

NCT07227012

PreclinicalRecruiting

Carcinoma, Renal Cell

NCT07227415

Q1 2031

Phase 3Not yet recruiting

Endometrial Neoplasms

NCT07578649

Phase 2Recruiting

Small Cell Lung Cancer

NCT07476287

Q3 2031

Phase 2Recruiting

Non-Small-Cell Lung

NCT07489066

Clinical

Trials by Indication[1]

Carcinoma, Renal Cell1 trial

AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA

Recruiting· Pfizer logo

Pfizer·Preclinical·NCT07227415·224 enrolled

Non-Small-Cell Lung1 trial

AN INTERVENTIONAL, OPEN-LABEL, PHASE 2 STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY OR IN COMBINATION IN ADULT PARTICIPANTS WITH EARLY-STAGE RESECTABLE OR LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER

Recruiting· Pfizer logo

Pfizer·Phase 2·NCT07489066·120 enrolled

Non-Small Cell Lung Carcinoma1 trial

AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Recruiting· Pfizer logo

Pfizer·Preclinical·NCT07227298·162 enrolled

Urothelial Cancer1 trial

AN INTERVENTIONAL PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, ANTITUMOR ACTIVITY, AND PHARMACOKINETICS OF PF 08634404 MONOTHERAPY OR IN COMBINATION WITH ENFORTUMAB VEDOTIN IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER

Recruiting· Pfizer logo

Pfizer·Preclinical·NCT07421700·132 enrolled

Intestinal Neoplasm1 trial

AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT07222800·800 enrolled

6 more indications

Small Cell Lung Cancer ( SCLC )1 trial

A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

Recruiting· Pfizer logo

Pfizer·Preclinical·NCT07226999·550 enrolled

Endometrial Neoplasms1 trial

AN INTERVENTIONAL PHASE 3, OPEN LABEL, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH ADVANCED OR RECURRENT MISMATCH REPAIR PROFICIENT ENDOMETRIAL CANCER

Not yet recruiting· Pfizer logo

Pfizer·Phase 3·NCT07578649·600 enrolled

Advanced Non-Small Cell Lung Cancer1 trial

AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT07222566·1,410 enrolled

Carcinoma, Hepatocellular1 trial

AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 AS MONOTHERAPY AND COMBINATION THERAPY IN ADULT PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA

Recruiting· Pfizer logo

Pfizer·Preclinical·NCT07227012·138 enrolled

Small Cell Lung Cancer1 trial

A PHASE 2 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED TRANSFORMED SMALL CELL LUNG CANCER

Recruiting· Pfizer logo

Pfizer·Phase 2·NCT07476287·40 enrolled

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma1 trial

A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA

Recruiting· Pfizer logo

Pfizer·Preclinical·NCT07392892·840 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for PF-08634404. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PF-08634404 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PF-08634404. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Pfizer

PF-08634404

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2028

Q1 2031

Q3 2031

Trials by Indication[1]

Carcinoma, Renal Cell1 trial

Non-Small-Cell Lung1 trial

Non-Small Cell Lung Carcinoma1 trial

Urothelial Cancer1 trial

Intestinal Neoplasm1 trial

Small Cell Lung Cancer ( SCLC )1 trial

Endometrial Neoplasms1 trial

Advanced Non-Small Cell Lung Cancer1 trial

Carcinoma, Hepatocellular1 trial

Small Cell Lung Cancer1 trial

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News